Femara

(Letrozole)

ApprovedSmall molecule

Letrozole is used to treat hormone receptor-positive breast cancer in postmenopausal women. It works by lowering estrogen levels in the body, which helps slow or stop the growth of breast cancer cells that depend on estrogen.[2] Femara is currently approved and in use across 63 indications[4].[1]

Femara is one of 641 small molecule programs targeting Ovarian Cancer. It is currently in Approved.

Indications

524

Total Trials

Active Trials

640

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Ovarian CancerTerminated

Metastatic Breast CancerActive, not recruiting

PregnancyUnknown status

AbemaciclibCompleted

Breast CarcinomaUnknown status

Habitual AbortionActive, not recruiting

Uterine FibroidApproved

AdenomyosisApproved

Follicular CystApproved

LeiomyosarcomaApproved

Ovarian CancerPhase 3

Terminated

Metastatic Breast CancerApproved

Active, not recruiting

PregnancyApproved

Unknown status

AbemaciclibPhase 2

Completed

Breast CarcinomaApproved

Unknown status

Habitual AbortionPreclinical

Active, not recruiting

Uterine FibroidApproved

Approved

AdenomyosisApproved

Approved

Follicular CystApproved

Approved

LeiomyosarcomaApproved

Approved

Showing 10 of 63 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Femara

Novartis

Approved

256 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Spravato

WWim Janssens

Preclinical

2 4

Tricor

JJagotec

Preclinical

1 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Tianeptine

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Breast Cancer

NCT03879577

Q4 2026

Phase 1Active, not recruiting

Breast Cancer

NCT06253195

Phase 3Active, not recruiting

Breast Cancer

NCT02246621

Phase 2Active, not recruiting

Breast Cancer

NCT02712723

Q2 2027

N/ARecruiting

Ovarian Cyst

NCT05487092

Q3 2027

Phase 2/3Active, not recruiting

Hyperplasia

NCT06390904

Clinical

Trials by Indication[1]

Breast Cancer111 trials

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Completed· Novartis logo

Novartis·Phase 2·NCT03056755·383 enrolled

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT03962647·31 enrolled

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Unknown status·JJinming Yu·Phase 2·NCT04095390·60 enrolled

Show 108 more trials

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Terminated·TTranslational Research in Oncology·Phase 2·NCT02115048·44 enrolled

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT02802748·60 enrolled

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Completed· Pfizer logo

Pfizer·Phase 3·NCT02297438·340 enrolled

Breast Cancer & Antiestrogenic Therapy & Brain

Not yet recruiting·IInternational Research Training Group 2804··NCT06346457·180 enrolled

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03128619·10 enrolled

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Recruiting·KKarolinska University Hospital·Phase 2·NCT05900206·370 enrolled

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

Terminated·AARCAGY/ GINECO GROUP·Phase 2·NCT02585388·120 enrolled

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT01105312·28 enrolled

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Completed· Pfizer logo

Pfizer·Phase 3·NCT02600923·131 enrolled

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Completed·—·Phase 2·NCT00903162·17 enrolled

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00265759·622 enrolled

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Active, not recruiting·NNSABP Foundation Inc·Phase 3·NCT00382070·3,966 enrolled

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT03007979·55 enrolled

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Completed·UUniversity of Washington·N/A·NCT01720602·15 enrolled

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Unknown status·NNational Cancer Centre, Singapore·Phase 2·NCT00687648·70 enrolled

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Unknown status·GGruppo Italiano Mammella (GIM)·Phase 3·NCT00541086·3,697 enrolled

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 2·NCT04191382·105 enrolled

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT03497702·114 enrolled

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Unknown status·FFudan University·Phase 3·NCT00902954·540 enrolled

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Completed·MMayo Clinic··NCT00719966·109 enrolled

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

Completed·UUNICANCER·Phase 3·NCT00673335·170 enrolled

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT03900884·17 enrolled

Letrozole After Tamoxifen in Treating Women With Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003140·5,187 enrolled

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 2·NCT01989780·160 enrolled

Study of Breast Cancer Prevention by Letrozole in High Risk Women

Completed·—·Phase 2·NCT00579826·55 enrolled

Breast Cancer Treatment Based on Organ-like Culture

Unknown status·XXijing Hospital··NCT03925233·300 enrolled

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01208441·28 enrolled

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03747042·61 enrolled

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT02246621·493 enrolled

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Active, not recruiting· BeiGene logo

BeiGene·Phase 1·NCT06253195·33 enrolled

Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

Terminated·MMassachusetts General Hospital·Phase 2·NCT00549822·3 enrolled

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT02278120·672 enrolled

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 2·NCT03633331·93 enrolled

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT03628066·24 enrolled

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

Completed·MMayo Clinic·Phase 2·NCT04294225·161 enrolled

Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene

Unknown status·KKorean Breast Cancer Study Group·Phase 4·NCT01072318·495 enrolled

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01013506

Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00332709·83 enrolled

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Terminated·WWashington University School of Medicine·Phase 2·NCT02907918·26 enrolled

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT02333370·88 enrolled

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Recruiting·UUniversity of Washington·Phase 4·NCT05183828·68 enrolled

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Completed·IInstitut Claudius Regaud·Phase 4·NCT01553903·29 enrolled

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Unknown status·—·Phase 2·NCT04942899·70 enrolled

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT02742051·40 enrolled

The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00171314·527 enrolled

A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer

Completed·—·Phase 2·NCT03306472·198 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00338728·59 enrolled

Fertility Preservation in Breast Cancer Patients

Completed·EErasme University Hospital·Phase 4·NCT02661932·65 enrolled

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03774472·15 enrolled

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Unknown status·ZZhiyong Yu·Phase 2/3·NCT03373708·200 enrolled

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

Completed·IImperial College London·Phase 3·NCT00963729·756 enrolled

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed·PPalleos Healthcare GmbH·Phase 2·NCT03272477·257 enrolled

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Active, not recruiting·—·Phase 2·NCT02778685·47 enrolled

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00433589·6,600 enrolled

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Terminated·OOncolytics Biotech·Phase 1·NCT04102618·26 enrolled

Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity

Withdrawn·UUniversitaire Ziekenhuizen KU Leuven·Phase 1·NCT04630210

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

Unknown status·FFudan University·Phase 1/2·NCT03772353·59 enrolled

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Completed·MMedical College of Wisconsin·Phase 2·NCT03219476·37 enrolled

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT03555877·56 enrolled

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00083993·1,236 enrolled

Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.

Not yet recruiting·—·Phase 2·NCT07394946·126 enrolled

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00498901·1 enrolled

A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer

Completed·LLund University Hospital·Phase 2·NCT02958852·126 enrolled

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00880009·16 enrolled

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Terminated· Novartis logo

Novartis·Phase 2·NCT01919229·14 enrolled

Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Completed·EETOP IBCSG Partners Foundation·Phase 3·NCT00004205·8,028 enrolled

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04256941·4 enrolled

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Completed·RRutgers, The State University of New Jersey·Phase 1/2·NCT00634634·52 enrolled

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Terminated· Novartis logo

Novartis·Phase 3·NCT03050398·8 enrolled

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01068704·4 enrolled

Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Completed·—··NCT00681928·72 enrolled

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 3·NCT02947685·518 enrolled

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT04258163·760 enrolled

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00721409·177 enrolled

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Completed·MMedSIR·Phase 2·NCT02491983·486 enrolled

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT03879577·53 enrolled

Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences··NCT02765373·500 enrolled

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease

Terminated·—·Phase 3·NCT02730091·98 enrolled

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Active, not recruiting·QQamar Khan·Phase 2·NCT02712723·121 enrolled

Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Withdrawn·TTechnical University of Munich·Phase 3·NCT00403182

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00332852·655 enrolled

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT00960960·71 enrolled

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Terminated· Roche logo

Roche·Phase 2·NCT00796107·6 enrolled

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

Unknown status·—·Phase 2·NCT00280930·60 enrolled

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Enrolling by invitation·PPeking University·Phase 2·NCT06650748·100 enrolled

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

Completed·—·N/A·NCT02010021·17 enrolled

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting·SSpanish Breast Cancer Research Group·Phase 2·NCT04293393·200 enrolled

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Completed· Novartis logo

Novartis·Phase 3·NCT00050011·602 enrolled

Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

Terminated· Novartis logo

Novartis·Phase 4·NCT00171847·93 enrolled

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT02520063·15 enrolled

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Terminated·PPalleos Healthcare GmbH·Phase 4·NCT03220178·532 enrolled

Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery

Completed·UUniversity of California, San Francisco·Phase 2·NCT00305825·43 enrolled

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00238316·68 enrolled

Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer

Unknown status·FFudan University··NCT01814449·130 enrolled

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

Completed· Novartis logo

Novartis·Phase 4·NCT00688909·261 enrolled

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT01684215·61 enrolled

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Completed·—·Phase 2·NCT02648477·30 enrolled

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01077453·112 enrolled

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Terminated·YYale University·Phase 2·NCT00461773·5 enrolled

Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer

Terminated·AAntisoma Research·Phase 2·NCT00770354·110 enrolled

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00073528·1,286 enrolled

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Completed·UUNICANCER·Phase 2·NCT02400567·125 enrolled

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00237211·31 enrolled

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07492394·60 enrolled

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03099174·133 enrolled

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT03554044·20 enrolled

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06760637·1,020 enrolled

Pregnancy8 trials

Letrozole in Tubal Ectopic Pregnancy

Unknown status·QQueen Mary Hospital, Hong Kong·Phase 3·NCT04341545·214 enrolled

The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy

Recruiting·KKK Women's and Children's Hospital·Phase 4·NCT05341817·144 enrolled

Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole + Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy

Completed·YYuzuncu Yil University·N/A·NCT06504082·60 enrolled

Show 5 more trials

Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy

Unknown status·TTehran University of Medical Sciences·Phase 1/2·NCT05918718·150 enrolled

Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy

Completed·ZZagazig University·N/A·NCT06426979·200 enrolled

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

Unknown status·—·N/A·NCT04308343·120 enrolled

Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy

Unknown status·TThe University of Hong Kong·N/A·NCT01475318·50 enrolled

Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT03901170·300 enrolled

Endometrial Cancer4 trials

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Completed·GGOG Foundation·Phase 2·NCT02228681·74 enrolled

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01068249·42 enrolled

Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00171808·26 enrolled

Show 1 more trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT04486352·148 enrolled

Endocrine Therapy4 trials

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Completed·FFondazione Sandro Pitigliani·Phase 2·NCT02549430·115 enrolled

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting·BBaylor Breast Care Center·Phase 2·NCT00999804·128 enrolled

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

Active, not recruiting·JJules Bordet Institute·Phase 2·NCT04551495·65 enrolled

Show 1 more trial

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Recruiting·YYongsheng Wang·Phase 4·NCT05809024·100 enrolled

Postmenopausal Women4 trials

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Completed· Novartis logo

Novartis·Phase 3·NCT02941926·3,246 enrolled

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00545077·380 enrolled

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

Completed·UUniversity of Virginia·N/A·NCT00114270

Show 1 more trial

Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

Unknown status·GGangnam Severance Hospital·Phase 2·NCT02214004·132 enrolled

53 more indications

Ovulation Induction3 trials

Letrozole Versus Clomifene Citrate for Ovulation Induction

Completed·UUniversity of Nottingham·Phase 4·NCT00478504·159 enrolled

Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women

Completed·—·Phase 3·NCT06486870·183 enrolled

Administration of Single High Dose Letrozole for Ovulation Induction

Completed·MMount Sinai Hospital, Canada·Phase 4·NCT02703649·36 enrolled

Abortion3 trials

Randomized Study of Letrozole and Trilostane for Medical Abortion

Terminated·KKristina Gemzell Danielsson·Phase 2·NCT01615211·36 enrolled

Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion

Completed·—·Phase 2/3·NCT02405156·400 enrolled

Different Methods of Termination of Second Trimester Abortion

Unknown status·—·N/A·NCT03400683·150 enrolled

Polycystic Ovary Syndrome3 trials

Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.

Completed·MMansoura University·N/A·NCT00956267·260 enrolled

Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome

Unknown status·—·Phase 3·NCT03009838·150 enrolled

Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)

Withdrawn·CCRG UZ Brussel·Phase 4·NCT04002635

Infertility3 trials

Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility

Completed· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 3·NCT00610077·55 enrolled

Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility

Completed·—·Phase 3·NCT02739516·108 enrolled

Graceful Lifestyle Changes Study for PCOS and Infertility

Unknown status·UUniversity of British Columbia·N/A·NCT02630485·240 enrolled

Ovarian Stimulation2 trials

Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

Completed·—·Phase 2/3·NCT02946684·129 enrolled

Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles

Completed·—·Phase 2/3·NCT02939898·33 enrolled

Embryo Transfer2 trials

Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer

Unknown status·NNavy General Hospital, Beijing·N/A·NCT02775877·100 enrolled

The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)

Recruiting·IInternational Peace Maternity and Child Health Hospital·N/A·NCT06006091·858 enrolled

Resistance2 trials

FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole

Completed·JJules Bordet Institute·Phase 2·NCT00199134·49 enrolled

Letrozole Versus Gonadotropins in Clomiphene Citrate Resistance

Completed·TTanta University·Phase 4·NCT04834791·70 enrolled

Miscarriage2 trials

Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage

Not yet recruiting·TThe University of Hong Kong·N/A·NCT06733727·884 enrolled

Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages

Unknown status·—·Phase 3·NCT05304273·120 enrolled

Obese1 trial

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT02538484·24 enrolled

Apatinib1 trial

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00499681·6 enrolled

Congenital Adrenal Hyperplasia1 trial

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00001521·66 enrolled

In Vitro Fertilization1 trial

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

Completed·NNew Hope Fertility Center·N/A·NCT02865681·4 enrolled

Hyperplasia1 trial

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Active, not recruiting·XXiaojun Chen·Phase 2/3·NCT06390904·29 enrolled

Fed1 trial

Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions

Completed·—·Phase 1·NCT01372982·36 enrolled

Endometriosis1 trial

Letrozole in the Treatment of Severe and Recurrent Endometriosis

Completed· Novartis logo

Novartis·Phase 2·NCT00240942·40 enrolled

Serous Carcinoma1 trial

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Completed·—·Phase 2/3·NCT03285802·1 enrolled

Intrauterine Insemination1 trial

Intrauterine Insemination With Letrozole Versus in Natural Cycle

Completed·PPeking University Third Hospital·N/A·NCT03455426·100 enrolled

Lymphangioleiomyomatosis1 trial

Letrozole for Lymphangioleiomyomatosis

Completed·UUniversity of Cincinnati·Phase 2·NCT01353209·17 enrolled

Precocious Puberty1 trial

Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 1·NCT00006174·25 enrolled

Intracytoplasmic Sperm Injection1 trial

Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles

Withdrawn·—·N/A·NCT04193930

Vitamin D Deficiency1 trial

Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00416715·100 enrolled

Musculoskeletal1 trial

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01194440·63 enrolled

Hepatopulmonary Syndrome1 trial

Letrozole in Patients With Hepatopulmonary Syndrome

Terminated·MMayo Clinic·Phase 2·NCT04577001·1 enrolled

Obesity1 trial

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT01758146·412 enrolled

Pancreatic Cancer1 trial

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06630325·30 enrolled

Fertility Preservation1 trial

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Recruiting·UUniversity of California, San Francisco·Phase 3·NCT03011684·309 enrolled

Bone Metastasis1 trial

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Completed·EEmory University·Phase 2·NCT03691493·36 enrolled

Ovarian Function1 trial

Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women

Completed·UUniversity of Saskatchewan·Phase 4·NCT01046578·41 enrolled

Advanced Solid Cancer1 trial

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02093351·79 enrolled

Overweight1 trial

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

Completed·UUniversity of Maryland, Baltimore·N/A·NCT02095184·42 enrolled

IVF Outcome1 trial

Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women

Unknown status·UUmm Al-Qura University·N/A·NCT05106712·700 enrolled

Breast Neoplasm1 trial

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Completed· Pfizer logo

Pfizer·Phase 2·NCT00062751·108 enrolled

Fasting Conditions1 trial

Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions

Completed·—·Phase 1·NCT01375452·36 enrolled

Polycystic Ovarian Syndrome1 trial

Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome

Completed·—·N/A·NCT01679574·200 enrolled

Ovarian cyst1 trial

Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy

Recruiting·TThe University of Hong Kong·N/A·NCT05487092·194 enrolled

Misoprostol1 trial

The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues

Completed·TThe University of Hong Kong·Phase 2·NCT02457312·20 enrolled

Clinical Trial1 trial

The Clinical Trial of Acupuncture Pre-treatment on PCOS

Completed·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT02491320·384 enrolled

PCOS1 trial

Letrozole Dose Increments in PCOS Patients Resistant to Letrozole

Completed·—·Phase 3·NCT06403488·102 enrolled

Endometrial1 trial

Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions

Unknown status·MMansoura University·Phase 4·NCT04364581·30 enrolled

Growth1 trial

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

Completed·SStanford University·Phase 4·NCT02137538·79 enrolled

Randomized1 trial

IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC

Completed·HHaukeland University Hospital·Phase 1·NCT03378297·26 enrolled

Treatment1 trial

Comparison of Treatment Modalities in Poor Responders Undergoing IVF

Completed·EErcan Bastu·N/A·NCT02158689·80 enrolled

Effectiveness1 trial

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Completed· Pfizer logo

Pfizer··NCT04176354·813 enrolled

Ovulation1 trial

Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole

Completed·—·Phase 3·NCT03241472·100 enrolled

Neoadjuvant1 trial

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT04614194·60 enrolled

Endocrinology1 trial

Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles

Withdrawn·UUniversity Hospitals Cleveland Medical Center·N/A·NCT02377479

Abemaciclib1 trial

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Completed·MMedSIR·Phase 2·NCT04603183·162 enrolled

Ovarian Tumor1 trial

Letrozole in Patients With Ovarian Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505661·16 enrolled

Primary Peritoneal Cancer1 trial

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNRG Oncology·Phase 3·NCT04095364·450 enrolled

Anovulation1 trial

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

Active, not recruiting·RRachel Mejia·Phase 4·NCT05206448·190 enrolled

Magnetic Resonance Imaging (MRI)1 trial

Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)

Completed·MMount Sinai Hospital, Canada·Phase 2·NCT01129622·16 enrolled

Outcome1 trial

Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?

Withdrawn·CCenter for Human Reproduction·Phase 4·NCT00804960

Unspecified5 trials

Antagonist/Letrozole in Poor Responders

Completed·YYazd Research & Clinical Center for Infertility·Phase 1/2·NCT00823004·120 enrolled

Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting·PProf. Wolfgang Janni·Phase 3·NCT02344472·271 enrolled

Hormone Secretion in Transgender Males

Withdrawn·UUniversity of California, San Diego·Phase 4·NCT04321551

Show 2 more trials

Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)

Unknown status·IInstitut fuer Frauengesundheit·Phase 4·NCT01908556·3,545 enrolled

The Letrozole Administration During Luteal Phase

Unknown status·TThe Affiliated Hospital of Inner Mongolia Medical University·Phase 3·NCT02686151·50 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 25, 1997

FEMARA

NDA NDA020726

Sources

References

[1]
ClinicalTrials.gov — 524 trial records for Letrozole. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Femara drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Letrozole compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Letrozole. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020726). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytochrome P450 19a1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Femara

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Breast Cancer111 trials

Pregnancy8 trials

Endometrial Cancer4 trials

Endocrine Therapy4 trials

Postmenopausal Women4 trials

Ovulation Induction3 trials

Abortion3 trials

Polycystic Ovary Syndrome3 trials

Infertility3 trials

Ovarian Stimulation2 trials

Embryo Transfer2 trials

Resistance2 trials

Miscarriage2 trials

Obese1 trial

Apatinib1 trial

Congenital Adrenal Hyperplasia1 trial

In Vitro Fertilization1 trial

Hyperplasia1 trial

Fed1 trial

Endometriosis1 trial

Serous Carcinoma1 trial

Intrauterine Insemination1 trial

Lymphangioleiomyomatosis1 trial

Precocious Puberty1 trial

Intracytoplasmic Sperm Injection1 trial

Vitamin D Deficiency1 trial

Musculoskeletal1 trial

Hepatopulmonary Syndrome1 trial

Obesity1 trial

Pancreatic Cancer1 trial

Fertility Preservation1 trial

Bone Metastasis1 trial

Ovarian Function1 trial

Advanced Solid Cancer1 trial

Overweight1 trial

IVF Outcome1 trial

Breast Neoplasm1 trial

Fasting Conditions1 trial

Polycystic Ovarian Syndrome1 trial

Ovarian cyst1 trial

Misoprostol1 trial

Clinical Trial1 trial

PCOS1 trial

Endometrial1 trial

Growth1 trial

Randomized1 trial

Treatment1 trial

Effectiveness1 trial

Ovulation1 trial

Neoadjuvant1 trial

Endocrinology1 trial

Abemaciclib1 trial

Ovarian Tumor1 trial

Primary Peritoneal Cancer1 trial

Anovulation1 trial

Magnetic Resonance Imaging (MRI)1 trial

Outcome1 trial

Unspecified5 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News